<p>Ligand Pharmaceuticals Incorporated (NASDAQ:LGND - 获取免费报告) 的股价在周四交易前出现下跌，原因是其财报低于预期。该股票此前收于 232.55 美元，但开盘价为 205.00 美元。Ligand Pharmaceuticals 的股票最后交易价格为 211.97 美元，成交量为 88,559 股。</p>
<p>获取 <strong>Ligand Pharmaceuticals</strong> 的提醒：</p>
<p>这家生物技术公司报告本季度每股收益为 1.63 美元，低于分析师一致预期的 1.84 美元，差距为 0.21 美元。该公司本季度的收入为 5172 万美元，而分析师预期为 5910 万美元。Ligand Pharmaceuticals 的股本回报率为 13.86%，净利润率为 46.42%。该公司的季度收入同比增长 14.1%。去年同期，该公司每股收益为 1.33 美元。</p>
<h2>分析师评级变动</h2>
<p>多位分析师最近对该股票发表了评论。HC Wainwright 在 2020 年 4 月 30 日的研究报告中将 Ligand Pharmaceuticals 的目标价从 243.00 美元上调至 289.00 美元，并给予该股票 “买入” 评级。Weiss Ratings 在 2020 年 5 月 1 日的研究报告中将 Ligand Pharmaceuticals 的评级从 “持有 (c)” 上调至 “持有 (c+)”。花旗在 2020 年 4 月 15 日的研究报告中将 Ligand Pharmaceuticals 的目标价从 276.00 美元上调至 282.00 美元，并给予该股票 “买入” 评级。Oppenheimer 在 2020 年 2 月 27 日的研究报告中将 Ligand Pharmaceuticals 的目标价从 275.00 美元上调至 277.00 美元，并给予该股票 “跑赢大盘” 评级。最后，美国银行在 2020 年 3 月 11 日的研究报告中开始覆盖 Ligand Pharmaceuticals 的股票，设定 “买入” 评级和 244.00 美元的目标价。七位分析师给予该股票 “买入” 评级，一位分析师给予 “持有” 评级。根据 MarketBeat.com 的数据，该股票的共识评级为 “适度买入”，平均目标价为 256.29 美元。</p>
<p><strong>查看我们最新的 LGND 股票报告</strong></p>
<h2>内部交易活动</h2>
<p>在相关消息中，董事 John W. Kozarich 在 2020 年 4 月 1 日以平均价格 202.23 美元出售了 467 股 Ligand Pharmaceuticals 的股票，总价值为 94,441.41 美元。出售后，该董事持有公司 42,253 股股票，价值约为 8,544,824.19 美元。此交易代表其持股比例下降了 1.09%。该交易已在证券交易委员会的法律文件中披露，可通过 SEC 网站访问。该交易是在预先安排的 10b5-1 交易计划下执行的。此外，内部人士 Andrew Reardon 在 2020 年 3 月 4 日以平均价格 206.35 美元出售了 5,000 股 Ligand Pharmaceuticals 的股票，总交易额为 1,031,750.00 美元。出售完成后，该内部人士直接持有公司 36,869 股股票，价值为 7,607,918.15 美元。这代表其持股比例下降了 11.94%。该销售的 SEC 文件提供了更多信息。内部人士在上个季度出售了 35,448 股公司股票，价值为 7,450,977 美元。公司内部人士持有公司 7.00% 的股份。</p>
<h2>机构投资者对 Ligand Pharmaceuticals 的看法</h2>
<p>多家机构投资者最近增加或减少了对 LGND 的持股。Envestnet Asset Management Inc.在第三季度将其在 Ligand Pharmaceuticals 的持股增加了 16.6%。Envestnet Asset Management Inc.目前持有 31,915 股该生物技术公司的股票，价值 5,653,000 美元，此前在上个季度购买了 4,538 股。Fisher Asset Management LLC 在第三季度将其在 Ligand Pharmaceuticals 的持股增加了 2.7%。Fisher Asset Management LLC 目前持有 108,926 股该生物技术公司的股票，价值 19,295,000 美元，此前在上个季度购买了 2,860 股。马萨诸塞金融服务公司在第三季度将其在 Ligand Pharmaceuticals 的持股增加了 59.5%。马萨诸塞金融服务公司目前持有 541,845 股该生物技术公司的股票，价值 95,982,000 美元，此前在上个季度购买了 202,103 股。Lisanti Capital Growth LLC 在第三季度将其在 Ligand Pharmaceuticals 的持股增加了 178.0%。Lisanti Capital Growth LLC 目前持有 29,677 股该生物技术公司的股票，价值 5,257,000 美元，此前在上个季度购买了 19,002 股。最后，Cibc World Market Inc.在第三季度将其在 Ligand Pharmaceuticals 的持股增加了 11.7%。Cibc World Market Inc.目前持有 59,131 股该生物技术公司的股票，价值 10,474,000 美元，此前在上个季度购买了 6,209 股。机构投资者和对冲基金持有公司 91.28% 的股份。</p>
<h2>Ligand Pharmaceuticals 股票表现</h2>
<p>该公司的债务与股本比率为 0.44，速动比率为 21.98，流动比率为 22.23。该公司的 50 日简单移动平均为 211.74 美元，200 日简单移动平均为 200.35 美元。该公司的市值为 42.9 亿美元，市盈率为 36.94，PEG 比率为 1.68，贝塔值为 1.20。</p>
<h2>关于 Ligand Pharmaceuticals</h2>
<p>(获取免费报告)</p>
<p>Ligand Pharmaceuticals, Inc 是一家生物制药公司，收购、开发和外许可专有技术，旨在帮助制药和生物技术公司发现和开发新药。Ligand 主要通过其研究服务和产生特许权使用费的业务运营，专注于建立多样化的技术平台组合，并与行业领导者合作，推动多个疾病领域的治疗候选药物的进展。</p>
<p>该公司的产品提供围绕几个核心平台。</p>
<h2>相关文章</h2>
<ul>
<li>我们更看好的五只股票，而非 Ligand Pharmaceuticals</li>
</ul>
<p><em>此即时新闻提醒由叙事科学技术和 MarketBeat 的金融数据生成，旨在为读者提供最快的报道和公正的覆盖。请将任何问题或意见发送至 contact@marketbeat.com.</em></p>
<h2>你现在应该投资$1,000 在 Ligand Pharmaceuticals 吗？</h2>
<p>在考虑 Ligand Pharmaceuticals 之前，你需要听听这个。</p>
<p>MarketBeat 每天跟踪华尔街顶级评级和表现最佳的研究分析师及其推荐给客户的股票。MarketBeat 已识别出五只顶级分析师悄悄建议客户现在购买的股票，以便在更广泛的市场注意到之前……而 Ligand Pharmaceuticals 并不在名单上。</p>
<p>虽然 Ligand Pharmaceuticals 目前在分析师中获得了中等买入评级，但顶级分析师认为这五只股票更值得购买。</p>
<p>在这里查看这五只股票</p>

Ligand制药

<p>Ligand Pharmaceuticals（纳斯达克代码：LGND）在报告令人失望的财报后，股价跳空下跌至 205.00 美元，盈利每股（EPS）为 1.63 美元，未能达到预期的 1.84 美元。收入为 5172 万美元，低于预期的 5910 万美元，尽管同比增长了 14.1%。分析师的评级意见不一，普遍共识为 “适度买入”，平均目标价为 256.29 美元。内部交易活动包括董事的股票出售，机构投资者持有 91.28% 的股份。该股票最后交易价为 211.97 美元，成交量为 88,559 股</p>

<p>Ligand Pharmaceuticals Incorporated (NASDAQ:LGND - Get Free Report)'s share price gapped down prior to trading on Thursday following a weaker than expected earnings announcement. The stock had previously closed at $232.55, but opened at $205.00. Ligand Pharmaceuticals shares last traded at $211.97, with a volume of 88,559 shares changing hands.</p>
<div class="lb-trans"><p>Ligand Pharmaceuticals Incorporated (NASDAQ:LGND - 获取免费报告) 的股价在周四交易前出现下跌，原因是其财报低于预期。该股票此前收于 232.55 美元，但开盘价为 205.00 美元。Ligand Pharmaceuticals 的股票最后交易价格为 211.97 美元，成交量为 88,559 股。</p>
</div><p>Get <strong>Ligand Pharmaceuticals</strong> alerts:</p>
<div class="lb-trans"><p>获取 <strong>Ligand Pharmaceuticals</strong> 的提醒：</p>
</div><p>The biotechnology company reported $1.63 EPS for the quarter, missing analysts' consensus estimates of $1.84 by ($0.21). The company had revenue of $51.72 million during the quarter, compared to analyst estimates of $59.10 million. Ligand Pharmaceuticals had a return on equity of 13.86% and a net margin of 46.42%.The firm's revenue for the quarter was up 14.1% on a year-over-year basis. During the same quarter last year, the business earned $1.33 earnings per share.</p>
<div class="lb-trans"><p>这家生物技术公司报告本季度每股收益为 1.63 美元，低于分析师一致预期的 1.84 美元，差距为 0.21 美元。该公司本季度的收入为 5172 万美元，而分析师预期为 5910 万美元。Ligand Pharmaceuticals 的股本回报率为 13.86%，净利润率为 46.42%。该公司的季度收入同比增长 14.1%。去年同期，该公司每股收益为 1.33 美元。</p>
</div><h2>Analyst Ratings Changes</h2>
<div class="lb-trans"><h2>分析师评级变动</h2>
</div><p>A number of analysts recently commented on the stock. HC Wainwright lifted their target price on shares of Ligand Pharmaceuticals from $243.00 to $289.00 and gave the stock a &#34;buy&#34; rating in a research note on Thursday, April 30th. Weiss Ratings raised shares of Ligand Pharmaceuticals from a &#34;hold (c)&#34; rating to a &#34;hold (c+)&#34; rating in a research report on Friday, May 1st. Citigroup raised their price target on shares of Ligand Pharmaceuticals from $276.00 to $282.00 and gave the stock a &#34;buy&#34; rating in a research report on Wednesday, April 15th. Oppenheimer raised their price target on shares of Ligand Pharmaceuticals from $275.00 to $277.00 and gave the stock an &#34;outperform&#34; rating in a research report on Friday, February 27th. Finally, Bank of America started coverage on shares of Ligand Pharmaceuticals in a research report on Wednesday, March 11th. They set a &#34;buy&#34; rating and a $244.00 price target for the company. Seven analysts have rated the stock with a Buy rating and one has given a Hold rating to the company's stock. According to MarketBeat.com, the stock has a consensus rating of &#34;Moderate Buy&#34; and an average target price of $256.29.</p>
<div class="lb-trans"><p>多位分析师最近对该股票发表了评论。HC Wainwright 在 2020 年 4 月 30 日的研究报告中将 Ligand Pharmaceuticals 的目标价从 243.00 美元上调至 289.00 美元，并给予该股票 “买入” 评级。Weiss Ratings 在 2020 年 5 月 1 日的研究报告中将 Ligand Pharmaceuticals 的评级从 “持有 (c)” 上调至 “持有 (c+)”。花旗在 2020 年 4 月 15 日的研究报告中将 Ligand Pharmaceuticals 的目标价从 276.00 美元上调至 282.00 美元，并给予该股票 “买入” 评级。Oppenheimer 在 2020 年 2 月 27 日的研究报告中将 Ligand Pharmaceuticals 的目标价从 275.00 美元上调至 277.00 美元，并给予该股票 “跑赢大盘” 评级。最后，美国银行在 2020 年 3 月 11 日的研究报告中开始覆盖 Ligand Pharmaceuticals 的股票，设定 “买入” 评级和 244.00 美元的目标价。七位分析师给予该股票 “买入” 评级，一位分析师给予 “持有” 评级。根据 MarketBeat.com 的数据，该股票的共识评级为 “适度买入”，平均目标价为 256.29 美元。</p>
</div><p><strong>Check Out Our Latest Stock Report on LGND</strong></p>
<div class="lb-trans"><p><strong>查看我们最新的 LGND 股票报告</strong></p>
</div><h2>Insider Activity</h2>
<div class="lb-trans"><h2>内部交易活动</h2>
</div><p>In related news, Director John W. Kozarich sold 467 shares of Ligand Pharmaceuticals stock in a transaction on Wednesday, April 1st. The shares were sold at an average price of $202.23, for a total value of $94,441.41. Following the sale, the director owned 42,253 shares of the company's stock, valued at approximately $8,544,824.19. This trade represents a 1.09% decrease in their position. The transaction was disclosed in a legal filing with the Securities &amp; Exchange Commission, which can be accessed through the SEC website. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Also, insider Andrew Reardon sold 5,000 shares of Ligand Pharmaceuticals stock in a transaction on Wednesday, March 4th. The shares were sold at an average price of $206.35, for a total transaction of $1,031,750.00. Following the completion of the sale, the insider directly owned 36,869 shares in the company, valued at $7,607,918.15. This represents a 11.94% decrease in their position. The SEC filing for this sale provides additional information. Insiders sold 35,448 shares of company stock valued at $7,450,977 in the last quarter. Company insiders own 7.00% of the company's stock.</p>
<div class="lb-trans"><p>在相关消息中，董事 John W. Kozarich 在 2020 年 4 月 1 日以平均价格 202.23 美元出售了 467 股 Ligand Pharmaceuticals 的股票，总价值为 94,441.41 美元。出售后，该董事持有公司 42,253 股股票，价值约为 8,544,824.19 美元。此交易代表其持股比例下降了 1.09%。该交易已在证券交易委员会的法律文件中披露，可通过 SEC 网站访问。该交易是在预先安排的 10b5-1 交易计划下执行的。此外，内部人士 Andrew Reardon 在 2020 年 3 月 4 日以平均价格 206.35 美元出售了 5,000 股 Ligand Pharmaceuticals 的股票，总交易额为 1,031,750.00 美元。出售完成后，该内部人士直接持有公司 36,869 股股票，价值为 7,607,918.15 美元。这代表其持股比例下降了 11.94%。该销售的 SEC 文件提供了更多信息。内部人士在上个季度出售了 35,448 股公司股票，价值为 7,450,977 美元。公司内部人士持有公司 7.00% 的股份。</p>
</div><h2>Institutional Investors Weigh In On Ligand Pharmaceuticals</h2>
<div class="lb-trans"><h2>机构投资者对 Ligand Pharmaceuticals 的看法</h2>
</div><p>A number of institutional investors have recently added to or reduced their stakes in LGND. Envestnet Asset Management Inc. boosted its stake in Ligand Pharmaceuticals by 16.6% during the 3rd quarter. Envestnet Asset Management Inc. now owns 31,915 shares of the biotechnology company's stock worth $5,653,000 after purchasing an additional 4,538 shares during the last quarter. Fisher Asset Management LLC boosted its stake in Ligand Pharmaceuticals by 2.7% during the 3rd quarter. Fisher Asset Management LLC now owns 108,926 shares of the biotechnology company's stock worth $19,295,000 after purchasing an additional 2,860 shares during the last quarter. Massachusetts Financial Services Co. MA boosted its stake in Ligand Pharmaceuticals by 59.5% during the 3rd quarter. Massachusetts Financial Services Co. MA now owns 541,845 shares of the biotechnology company's stock worth $95,982,000 after purchasing an additional 202,103 shares during the last quarter. Lisanti Capital Growth LLC boosted its stake in Ligand Pharmaceuticals by 178.0% during the 3rd quarter. Lisanti Capital Growth LLC now owns 29,677 shares of the biotechnology company's stock worth $5,257,000 after purchasing an additional 19,002 shares during the last quarter. Finally, Cibc World Market Inc. boosted its stake in Ligand Pharmaceuticals by 11.7% during the 3rd quarter. Cibc World Market Inc. now owns 59,131 shares of the biotechnology company's stock worth $10,474,000 after purchasing an additional 6,209 shares during the last quarter. Institutional investors and hedge funds own 91.28% of the company's stock.</p>
<div class="lb-trans"><p>多家机构投资者最近增加或减少了对 LGND 的持股。Envestnet Asset Management Inc.在第三季度将其在 Ligand Pharmaceuticals 的持股增加了 16.6%。Envestnet Asset Management Inc.目前持有 31,915 股该生物技术公司的股票，价值 5,653,000 美元，此前在上个季度购买了 4,538 股。Fisher Asset Management LLC 在第三季度将其在 Ligand Pharmaceuticals 的持股增加了 2.7%。Fisher Asset Management LLC 目前持有 108,926 股该生物技术公司的股票，价值 19,295,000 美元，此前在上个季度购买了 2,860 股。马萨诸塞金融服务公司在第三季度将其在 Ligand Pharmaceuticals 的持股增加了 59.5%。马萨诸塞金融服务公司目前持有 541,845 股该生物技术公司的股票，价值 95,982,000 美元，此前在上个季度购买了 202,103 股。Lisanti Capital Growth LLC 在第三季度将其在 Ligand Pharmaceuticals 的持股增加了 178.0%。Lisanti Capital Growth LLC 目前持有 29,677 股该生物技术公司的股票，价值 5,257,000 美元，此前在上个季度购买了 19,002 股。最后，Cibc World Market Inc.在第三季度将其在 Ligand Pharmaceuticals 的持股增加了 11.7%。Cibc World Market Inc.目前持有 59,131 股该生物技术公司的股票，价值 10,474,000 美元，此前在上个季度购买了 6,209 股。机构投资者和对冲基金持有公司 91.28% 的股份。</p>
</div><h2>Ligand Pharmaceuticals Stock Performance</h2>
<div class="lb-trans"><h2>Ligand Pharmaceuticals 股票表现</h2>
</div><p>The company has a debt-to-equity ratio of 0.44, a quick ratio of 21.98 and a current ratio of 22.23. The firm's 50 day simple moving average is $211.74 and its 200-day simple moving average is $200.35. The company has a market cap of $4.29 billion, a price-to-earnings ratio of 36.94, a PEG ratio of 1.68 and a beta of 1.20.</p>
<div class="lb-trans"><p>该公司的债务与股本比率为 0.44，速动比率为 21.98，流动比率为 22.23。该公司的 50 日简单移动平均为 211.74 美元，200 日简单移动平均为 200.35 美元。该公司的市值为 42.9 亿美元，市盈率为 36.94，PEG 比率为 1.68，贝塔值为 1.20。</p>
</div><h2>About Ligand Pharmaceuticals</h2>
<div class="lb-trans"><h2>关于 Ligand Pharmaceuticals</h2>
</div><p>(Get Free Report)</p>
<div class="lb-trans"><p>(获取免费报告)</p>
</div><p>Ligand Pharmaceuticals, Inc is a biopharmaceutical company that acquires, develops and out-licenses proprietary technologies designed to help pharmaceutical and biotechnology companies discover and develop novel medicines. Operating primarily through its research services and royalty-generating businesses, Ligand focuses on building a diversified portfolio of technology platforms and partnering with industry leaders to advance therapeutic candidates across multiple disease areas.</p>
<div class="lb-trans"><p>Ligand Pharmaceuticals, Inc 是一家生物制药公司，收购、开发和外许可专有技术，旨在帮助制药和生物技术公司发现和开发新药。Ligand 主要通过其研究服务和产生特许权使用费的业务运营，专注于建立多样化的技术平台组合，并与行业领导者合作，推动多个疾病领域的治疗候选药物的进展。</p>
</div><p>The company's product offerings center around several core platforms.</p>
<div class="lb-trans"><p>该公司的产品提供围绕几个核心平台。</p>
</div><h2>Featured Articles</h2>
<div class="lb-trans"><h2>相关文章</h2>
</div><ul>
<li>Five stocks we like better than Ligand Pharmaceuticals</li>
</ul>
<div class="lb-trans"><ul>
<li>我们更看好的五只股票，而非 Ligand Pharmaceuticals</li>
</ul>
</div><p><em>This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.</em></p>
<div class="lb-trans"><p><em>此即时新闻提醒由叙事科学技术和 MarketBeat 的金融数据生成，旨在为读者提供最快的报道和公正的覆盖。请将任何问题或意见发送至 contact@marketbeat.com.</em></p>
</div><h2>Should You Invest $1,000 in Ligand Pharmaceuticals Right Now?</h2>
<div class="lb-trans"><h2>你现在应该投资$1,000 在 Ligand Pharmaceuticals 吗？</h2>
</div><p>Before you consider Ligand Pharmaceuticals, you'll want to hear this.</p>
<div class="lb-trans"><p>在考虑 Ligand Pharmaceuticals 之前，你需要听听这个。</p>
</div><p>MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Ligand Pharmaceuticals wasn't on the list.</p>
<div class="lb-trans"><p>MarketBeat 每天跟踪华尔街顶级评级和表现最佳的研究分析师及其推荐给客户的股票。MarketBeat 已识别出五只顶级分析师悄悄建议客户现在购买的股票，以便在更广泛的市场注意到之前……而 Ligand Pharmaceuticals 并不在名单上。</p>
</div><p>While Ligand Pharmaceuticals currently has a Moderate Buy rating among analysts, top-rated analysts believe these five stocks are better buys.</p>
<div class="lb-trans"><p>虽然 Ligand Pharmaceuticals 目前在分析师中获得了中等买入评级，但顶级分析师认为这五只股票更值得购买。</p>
</div><p>View The Five Stocks Here</p>
<div class="lb-trans"><p>在这里查看这五只股票</p>
</div>

Ligand 制药（NASDAQ:LGND）在收益未达预期后股价出现跳空下跌